Zymeworks Guides FY26 Total Sales, Including Collaboration Revenue From YUPELRI, Of $278M-$292M And Adjusted EBITDA Of $114M-$128M
Zymeworks Inc. (NASDAQ: ZYME ), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the final transaction details and updated financial guidance following the completion of its acquisition of Theravance